Nimodipine
As of the edition of 20 October 2026, Nimodipine is a small molecule: marketed, first approved in 1987 (CH); acts on CACNA1C, CACNA1D and CACNA1F and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Nimotop
- First approved
- 6 May 1987 (CH)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Azurity Pharmaceuticals; 5 holders in all
- Registered trials
- 24, 4 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Mental health; Chemically induced; Urinary and reproductive; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Nimodipine.
See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1F | Voltage-dependent L-type calcium channel subunit alpha-1F | O60840 |
| NR3C2 | Mineralocorticoid receptor | P08235 |
| CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Q01668 |
| CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Q13698 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Q13936 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 2 | 1 |
| Phase 1 | 7 | 5 | 1 | 0 |
| Phase 2 | 6 | 2 | 2 | 2 |
| Phase 3 | 1 | 0 | 1 | 0 |
| Phase 4 | 4 | 2 | 0 | 1 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant | 1988 to now |
| Arbor Pharmaceuticals | Later holder | 2013 to now |
| Azurity Pharmaceuticals | Acquired holder | 2022 to now |